{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:24:12Z","timestamp":1792614252565,"version":"4.5.0"},"reference-count":80,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG000333"],"award-info":[{"award-number":["AG000333"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"award":["AG000333"],"award-info":[{"award-number":["AG000333"]}],"id":[{"id":"https:\/\/ror.org\/049v75w11","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1ZIADA000618"],"award-info":[{"award-number":["1ZIADA000618"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"award":["1ZIADA000618"],"award-info":[{"award-number":["1ZIADA000618"]}],"id":[{"id":"https:\/\/ror.org\/00fq5cm18","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>GLP-1 receptor (GLP-1R) agonists, widely used for diabetes and obesity management, have shown preclinical and clinical promise as potential therapeutics for neurological conditions. Until 2026, all U.S. Food and Drug Administration (FDA)-approved GLP-1 drugs were peptide-based, with most requiring daily or weekly subcutaneous injections. Despite their large size and low brain penetrance, several peptide-based GLP-1 drugs are in clinical trials for neurologic indications. Recently, the FDA approved orforglipron as the first small-molecule, non-peptide, orally bioavailable human GLP-1 receptor agonist, and it may offer advantages over peptide-based counterparts. We hence evaluated whether it possesses similar neurotrophic, neuroprotective, and anti-inflammatory attributes. Herein, we utilized human-derived neuronal and microglial cell lines to investigate these properties. Orforglipron activated cAMP signaling and shielded neuronal cells from excitotoxic glutamate and oxidative stress, which are common in neurodegenerative diseases and injuries. Additionally, orforglipron effectively mitigated LPS- and glutamate-induced proinflammatory protein secretion (IL-6, IL-8, and MCP-1) from a human microglial cell line. Actions were replicated under insulin resistance\u2014a potential cause of neurodegenerative conditions\u2014in which orforglipron significantly upregulated phosphorylation of protein kinase B (Akt), providing an additional neuroprotective mechanism. Measured orforglipron brain uptake in rat was low (brain\/plasma and CSF\/plasma ratios: 0.0078), and in the ballpark of peptide-based GLP-1 drugs. Nevertheless, orforglipron may provide potential value in specific neurological conditions.<\/jats:p>","DOI":"10.3390\/cells15141301","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:35:52Z","timestamp":1784630152000},"page":"1301","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Orforglipron, a Small-Molecule Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA), Has Neuroprotective and Anti-Inflammatory Effects"],"prefix":"10.3390","volume":"15","author":[{"given":"Yazhou","family":"Li","sequence":"first","affiliation":[{"name":"Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5125-8720","authenticated-orcid":false,"given":"Elliot J.","family":"Glotfelty","sequence":"additional","affiliation":[{"name":"Cellular Stress and Inflammation Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pathik","family":"Parekh","sequence":"additional","affiliation":[{"name":"Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1505-9334","authenticated-orcid":false,"given":"Buyandelger","family":"Batsaikhan","sequence":"additional","affiliation":[{"name":"Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Luo","sequence":"additional","affiliation":[{"name":"Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley N.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Translational Analytical Core, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon K.","family":"Harvey","sequence":"additional","affiliation":[{"name":"Cellular Stress and Inflammation Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3032-1468","authenticated-orcid":false,"given":"Nigel H.","family":"Greig","sequence":"additional","affiliation":[{"name":"Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref_1","unstructured":"FDA (2026, June 17). FDA Approves First New Molecular Entity Under National Priority Voucher Program, Action Marks the Fastest Approval of an NME Since 2002, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"eadp5765","DOI":"10.1126\/scitranslmed.adp5765","article-title":"The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron","volume":"16","author":"Sloop","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_3","unstructured":"NovoNordisk (2026, June 17). Wegovy Perscribing Information (Oral 25 mg). Available online: https:\/\/www.novo-pi.com\/wegovy.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","article-title":"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes","volume":"393","author":"Rosenstock","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(26)00202-3","article-title":"Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): A multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial","volume":"407","author":"Rosenstock","year":"2026","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/dom.14244","article-title":"Patients\u2019 preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study","volume":"23","author":"Boye","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/13543784.2020.1738383","article-title":"Brain insulin resistance: Role in neurodegenerative disease and potential for targeting","volume":"29","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/jgs.18306","article-title":"Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies","volume":"71","author":"Tang","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_11","first-page":"e12268","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"Friedrich","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson\u2019s disease: A cohort study of patients with diabetes","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/mds.26734","article-title":"Reduced incidence of Parkinson\u2019s disease after dipeptidyl peptidase-4 inhibitors\u2014A nationwide case-control study","volume":"31","author":"Svenningsson","year":"2016","journal-title":"Mov. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma","volume":"107","author":"Sterling","year":"2023","journal-title":"Br. J. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s00415-020-09813-4","article-title":"GLP-1 receptor agonists in diabetes for stroke prevention: A systematic review and meta-analysis","volume":"267","author":"Malhotra","year":"2020","journal-title":"J. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/ene.13905","article-title":"Protection against stroke with glucagon-like peptide 1 receptor agonists: A systematic review and meta-analysis","volume":"26","author":"Barkas","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1021\/acsptsci.9b00003","article-title":"Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury","volume":"2","author":"Glotfelty","year":"2019","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/13543784.2020.1764534","article-title":"Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson\u2019s disease","volume":"29","author":"Glotfelty","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"106550","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102343","DOI":"10.1016\/j.arr.2024.102343","article-title":"Type 2 diabetes mellitus\/obesity drugs: A neurodegenerative disorders savior or a bridge too far?","volume":"98","author":"Kopp","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40263-025-01226-z","article-title":"Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer\u2019s Disease and Parkinson\u2019s Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1\/GIP Receptor Agonists as Potential Disease-Modifying Therapies","volume":"39","year":"2025","journal-title":"CNS Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e194745","DOI":"10.1172\/JCI194745","article-title":"The promise of GLP-1 receptor agonists for neurodegenerative diseases","volume":"136","author":"Athauda","year":"2026","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.nbd.2018.11.023","article-title":"Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury","volume":"124","author":"Bader","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10722","DOI":"10.1038\/s41598-018-28449-z","article-title":"Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson\u2019s disease","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/jnc.15521","article-title":"The metabolite GLP-1 (9-36) is neuroprotective and anti-inflammatory in cellular models of neurodegeneration","volume":"159","author":"Li","year":"2021","journal-title":"J. Neurochem."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Yu, S.-J., Chen, S., Yang, Y.-Y., Glotfelty, E.J., Jung, J., Kim, H.K., Choi, H.-I., Choi, D.-S., Hoffer, B.J., and Greig, N.H. (2020). PT320, sustained release Exendin-4, mitigates L-DOPA-induced dyskinesia in a rat 6-hydroxydopamine model of Parkinson\u2019s disease. Front. Neurosci., 14.","DOI":"10.3389\/fnins.2020.00785"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1124\/jpet.102.037481","article-title":"Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4","volume":"302","author":"Perry","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1124\/jpet.300.3.958","article-title":"A novel neurotrophic property of glucagon-like peptide 1: A promoter of nerve growth factor-mediated differentiation in PC12 cells","volume":"300","author":"Perry","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/jnr.10611","article-title":"Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron","volume":"72","author":"Perry","year":"2003","journal-title":"J. Neurosci. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease","volume":"24","author":"Yun","year":"2018","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kopp, K.O., Li, Y., Glotfelty, E.J., Tweedie, D., and Greig, N.H. (2024). Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration. Biomolecules, 14.","DOI":"10.3390\/biom14070872"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2017.06.029","article-title":"A novel GLP-1\/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson\u2019s disease","volume":"812","author":"Yuan","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.7150\/ijbs.27774","article-title":"GLP-1 treatment protects endothelial cells from oxidative stress-induced autophagy and endothelial dysfunction","volume":"14","author":"Cai","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cmet.2006.10.001","article-title":"GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress","volume":"4","author":"Yusta","year":"2006","journal-title":"Cell Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson\u2019s disease","volume":"86","author":"Bertilsson","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"ref_38","first-page":"407152","article-title":"Neuroprotection by Exendin-4 Is GLP-1 Receptor Specific but DA D3 Receptor Dependent, Causing Altered BrdU Incorporation in Subventricular Zone and Substantia Nigra","volume":"2013","author":"Harkavyi","year":"2013","journal-title":"J. Neurodegener. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejphar.2009.12.023","article-title":"Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer\u2019s disease","volume":"630","author":"McClean","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejphar.2018.03.024","article-title":"DA5-CH, a novel GLP-1\/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP\/PS1 mouse model of Alzheimer\u2019s disease","volume":"827","author":"Cao","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"104640","DOI":"10.1016\/j.yhbeh.2019.104640","article-title":"A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP\/PS1 transgenic mice","volume":"118","author":"Wang","year":"2020","journal-title":"Horm. Behav."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.1471-4159.2010.06731.x","article-title":"Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells","volume":"113","author":"Li","year":"2010","journal-title":"J. Neurochem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1038\/s41598-021-85018-7","article-title":"Palmitic acid promotes resistin-induced insulin resistance and inflammation in SH-SY5Y human neuroblastoma","volume":"11","author":"Amine","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_44","first-page":"53199","article-title":"Monitoring Endoplasmic Reticulum Calcium Homeostasis Using a Gaussia Luciferase SERCaMP","volume":"103","author":"Henderson","year":"2015","journal-title":"J. Vis. Exp."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"a004317","DOI":"10.1101\/cshperspect.a004317","article-title":"Endoplasmic-reticulum calcium depletion and disease","volume":"3","author":"Mekahli","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jnc.16093","article-title":"Excitotoxic glutamate levels cause the secretion of resident endoplasmic reticulum proteins","volume":"168","author":"Dossat","year":"2024","journal-title":"J. Neurochem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"109040","DOI":"10.1016\/j.celrep.2021.109040","article-title":"A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome","volume":"35","author":"Henderson","year":"2021","journal-title":"Cell Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.celrep.2018.10.055","article-title":"KDEL receptors are differentially regulated to maintain the ER proteome under calcium deficiency","volume":"25","author":"Trychta","year":"2018","journal-title":"Cell Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1111\/dom.15184","article-title":"Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants","volume":"25","author":"Pratt","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"106121","DOI":"10.1016\/j.ebiom.2026.106121","article-title":"Generation and characterisation of a humanised GLP-1 receptor mouse model for translational drug development","volume":"124","author":"Sonne","year":"2026","journal-title":"EBioMedicine"},{"key":"ref_51","unstructured":"WHO (2026, April 13). Dementia Fact Sheet. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41574-021-00498-x","article-title":"Brain insulin signalling in metabolic homeostasis and disease","volume":"17","author":"Scherer","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Li, L., He, H., and Wang, Y. (2026). Insulin and IGF signaling in the brain: Multilevel regulation of synaptic and network homeostasis. Front. Endocrinol., 17.","DOI":"10.3389\/fendo.2026.1793536"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000150441","article-title":"The role of PI3\/Akt pathway in the protective effect of insulin against corticosterone cell death induction in hippocampal cell culture","volume":"88","author":"Moosavi","year":"2008","journal-title":"Neuroendocrinology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jalz.2013.12.007","article-title":"The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer\u2019s disease","volume":"10","author":"Talbot","year":"2014","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/alz.12474","article-title":"Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon-like peptide-1 receptor agonists","volume":"18","author":"Yassine","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist","volume":"117","author":"Kawai","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Kansakar, U., Jankauskas, S.S., Pande, S., Mone, P., Varzideh, F., and Santulli, G. (2026). Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27031409"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1471-4159.2004.02914.x","article-title":"The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem","volume":"92","author":"Alvarez","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"341","DOI":"10.32598\/bcn.2021.2554.2","article-title":"Investigating the Glucagon-like Peptide-1 and Its Receptor in Human Brain: Distribution of Expression, Functional Implications, Age-related Changes and Species Specific Characteristics","volume":"14","author":"Gupta","year":"2023","journal-title":"Basic Clin. Neurosci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.expneurol.2016.11.010","article-title":"Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke","volume":"288","author":"Li","year":"2017","journal-title":"Exp. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.expneurol.2016.11.005","article-title":"Novel GLP-1R\/GIPR co-agonist \u201ctwincretin\u201d is neuroprotective in cell and rodent models of mild traumatic brain injury","volume":"288","author":"Tamargo","year":"2017","journal-title":"Exp. Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/0-387-30128-3_10","article-title":"Neuroprotection by cAMP: Another brick in the wall","volume":"557","author":"Silveira","year":"2006","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nrneurol.2017.99","article-title":"ER stress and the unfolded protein response in neurodegeneration","volume":"13","author":"Hetz","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1523\/JNEUROSCI.4289-06.2007","article-title":"Endoplasmic reticulum stress inhibition protects against excitotoxic neuronal injury in the rat brain","volume":"27","author":"Sokka","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0361-9230(85)90153-4","article-title":"Peptides and the blood-brain barrier: Lipophilicity as a predictor of permeability","volume":"15","author":"Banks","year":"1985","journal-title":"Brain Res. Bull."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"101760","DOI":"10.1016\/j.xcrm.2024.101760","article-title":"The penetration of therapeutics across the blood-brain barrier: Classic case studies and clinical implications","volume":"5","author":"Banks","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2292461","DOI":"10.1080\/21688370.2023.2292461","article-title":"Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"12","author":"Rhea","year":"2024","journal-title":"Tissue Barriers"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"114187","DOI":"10.1016\/j.bcp.2020.114187","article-title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics","volume":"180","author":"Salameh","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: A phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of Lixisenatide in Early Parkinson\u2019s Disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Hogg, E., Wu, T., Bresee, C., Wertheimer, J., Malatt, C., Tan, E., Pomeroy, H., Nuno, M., Wyse, R., and Tagliati, M. (2022). A Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Liraglutide in Parkinson\u2019s Disease. SSRN, preprints.","DOI":"10.2139\/ssrn.4212371"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","article-title":"Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial","volume":"23","author":"McGarry","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_75","unstructured":"Chang, M. (2026, June 17). Despite failing phase 2a clinical trials, Peptron not giving up on Parkinson\u2019s treatment. Korea Biomedical Review, Available online: https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=20071."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Gejl, M., Gjedde, A., Egefjord, L., M\u00f8ller, A., Hansen, S.B., Vang, K., Rodell, A., Br\u00e6ndgaard, H., Gottrup, H., and Schacht, A. (2016). In Alzheimer\u2019s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial. Front. Aging Neurosci., 8.","DOI":"10.3389\/fnagi.2016.00108"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease","volume":"123","author":"Dickson","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","article-title":"Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery","volume":"7","author":"Wager","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e1594","DOI":"10.1002\/cpdd.1594","article-title":"Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants","volume":"15","author":"Morse","year":"2026","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/bdd.2331","article-title":"The role of the efflux transporter, P-glycoprotein, at the blood-brain barrier in drug discovery","volume":"44","author":"Cox","year":"2023","journal-title":"Biopharm. Drug Dispos."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/14\/1301\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:50:26Z","timestamp":1784631026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/14\/1301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":80,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cells15141301"],"URL":"https:\/\/doi.org\/10.3390\/cells15141301","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}